|
CN113679717A
(zh)
|
2012-08-22 |
2021-11-23 |
康奈尔大学 |
用于抑制肌成束蛋白的方法
|
|
CN104981458B
(zh)
|
2012-10-02 |
2017-07-21 |
吉利德科学公司 |
组蛋白去甲基化酶抑制剂
|
|
HUE037312T2
(hu)
|
2012-12-19 |
2018-08-28 |
Celgene Quanticel Res Inc |
Hiszton demetiláz inhibitorok
|
|
KR20150100814A
(ko)
|
2012-12-21 |
2015-09-02 |
콴티셀 파마슈티컬스, 인크. |
히스톤 데메틸라제 억제제
|
|
SG10201707027SA
(en)
|
2013-02-27 |
2017-09-28 |
Epitherapeutics Aps |
Inhibitors of histone demethylases
|
|
EP2968282B1
(en)
|
2013-03-12 |
2018-05-09 |
Celgene Quanticel Research, Inc. |
Histone dementhylase inhibitors
|
|
EP2970307B1
(en)
|
2013-03-13 |
2020-03-11 |
Genentech, Inc. |
Pyrazolo compounds and uses thereof
|
|
CA2940144C
(en)
|
2014-02-20 |
2023-06-13 |
Cornell University |
Substituted indazol-3-yl derivatives and pharmaceutical compositions thereof useful as inhibitor of fascin
|
|
NZ728120A
(en)
|
2014-06-25 |
2023-06-30 |
Celgene Quanticel Res Inc |
Histone demethylase inhibitors
|
|
KR20170040805A
(ko)
|
2014-08-27 |
2017-04-13 |
길리애드 사이언시즈, 인코포레이티드 |
히스톤 데메틸라제를 억제하기 위한 화합물 및 방법
|
|
US10030017B2
(en)
|
2014-09-17 |
2018-07-24 |
Celgene Quanticel Research, Inc. |
Histone demethylase inhibitors
|
|
KR20170048591A
(ko)
|
2014-09-17 |
2017-05-08 |
셀젠 콴티셀 리서치, 인크. |
히스톤 데메틸라제 억제제
|
|
ES2751464T3
(es)
|
2014-09-17 |
2020-03-31 |
Celgene Quanticel Res Inc |
Inhibidores de histona desmetilasa
|
|
CN108698997A
(zh)
|
2015-12-28 |
2018-10-23 |
赛尔基因昆蒂赛尔研究公司 |
组蛋白脱甲基酶抑制剂
|
|
CN105601555B
(zh)
*
|
2016-03-14 |
2018-07-31 |
苏州大学 |
一种制备硝基吲哚衍生物的方法
|
|
JP6970681B2
(ja)
*
|
2016-03-15 |
2021-11-24 |
セルジーン クオンティセル リサーチ，インク． |
ヒストンデメチラーゼ阻害剤
|
|
US10150754B2
(en)
|
2016-04-19 |
2018-12-11 |
Celgene Quanticel Research, Inc. |
Histone demethylase inhibitors
|
|
ES2969239T3
(es)
|
2016-05-27 |
2024-05-17 |
Gilead Sciences Inc |
Combinación de ledipasvir y sofosbuvir para su uso en el tratamiento de infecciones por el virus de la hepatitis B en humanos
|
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
ES2826748T3
(es)
|
2016-09-02 |
2021-05-19 |
Gilead Sciences Inc |
Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
|
|
KR102268448B1
(ko)
|
2016-09-02 |
2021-06-22 |
길리애드 사이언시즈, 인코포레이티드 |
톨 유사 수용체 조정제 화합물
|
|
MA46535A
(fr)
|
2016-10-14 |
2019-08-21 |
Prec Biosciences Inc |
Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b
|
|
EP3535242B1
(en)
*
|
2016-10-20 |
2024-01-24 |
B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University |
Dna primase and gyrase inhibitors
|
|
TWI868958B
(zh)
|
2017-01-31 |
2025-01-01 |
美商基利科學股份有限公司 |
替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
|
|
JOP20180008A1
(ar)
|
2017-02-02 |
2019-01-30 |
Gilead Sciences Inc |
مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
|
|
WO2018149986A1
(en)
*
|
2017-02-16 |
2018-08-23 |
Oryzon Genomics, S.A. |
2-(bicyclo-heteroaryl)-isonicotinic derivatives as histone demethylase inhibitors
|
|
JP7442439B2
(ja)
|
2017-03-30 |
2024-03-04 |
アルベルト－ルートヴィヒ－ユニバーシティー フライブルク |
Ｋｄｍ４阻害剤
|
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
|
CN111511754B
(zh)
|
2017-12-20 |
2023-09-12 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
|
|
EP3728283B1
(en)
|
2017-12-20 |
2023-11-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
WO2019160882A1
(en)
|
2018-02-13 |
2019-08-22 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
KR102526964B1
(ko)
|
2018-02-26 |
2023-04-28 |
길리애드 사이언시즈, 인코포레이티드 |
Hbv 복제 억제제로서의 치환된 피롤리진 화합물
|
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TW201945388A
(zh)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
|
|
WO2019204609A1
(en)
|
2018-04-19 |
2019-10-24 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
BR112020026746A2
(pt)
|
2018-07-13 |
2021-03-30 |
Gilead Sciences, Inc. |
Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição.
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
CN112955435B
(zh)
|
2018-10-24 |
2024-09-06 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
|
KR102658602B1
(ko)
|
2018-10-31 |
2024-04-19 |
길리애드 사이언시즈, 인코포레이티드 |
Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
|
|
FI3873903T3
(fi)
|
2018-10-31 |
2024-03-26 |
Gilead Sciences Inc |
Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
|
|
EP3935065A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
EP3934757B1
(en)
|
2019-03-07 |
2023-02-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
CA3129011C
(en)
|
2019-03-07 |
2023-12-19 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
|
MX2021015452A
(es)
|
2019-06-25 |
2022-02-11 |
Gilead Sciences Inc |
Proteinas de fusion flt3l-fc y metodos de uso.
|
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
WO2021034804A1
(en)
|
2019-08-19 |
2021-02-25 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
KR20220074917A
(ko)
|
2019-09-30 |
2022-06-03 |
길리애드 사이언시즈, 인코포레이티드 |
Hbv 백신 및 hbv를 치료하는 방법
|
|
DK4069729T3
(da)
|
2019-12-06 |
2025-04-07 |
Prec Biosciences Inc |
Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
|
|
AR121620A1
(es)
|
2020-03-20 |
2022-06-22 |
Gilead Sciences Inc |
Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos
|
|
JP7712352B2
(ja)
|
2020-08-07 |
2025-07-23 |
ギリアード サイエンシーズ， インコーポレイテッド |
ホスホンアミドヌクレオチド類似体のプロドラッグ及びその薬学的使用
|
|
TW202406932A
(zh)
|
2020-10-22 |
2024-02-16 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
EP4337223A1
(en)
|
2021-05-13 |
2024-03-20 |
Gilead Sciences, Inc. |
Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
AU2022298639C1
(en)
|
2021-06-23 |
2025-07-17 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
KR20240025616A
(ko)
|
2021-06-23 |
2024-02-27 |
길리애드 사이언시즈, 인코포레이티드 |
다이아실글리세롤 키나제 조절 화합물
|
|
AU2022299051B2
(en)
|
2021-06-23 |
2025-03-13 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
PE20251709A1
(es)
|
2022-11-21 |
2025-07-02 |
Nippon Shinyaku Co Ltd |
Compuesto que sirve como inhibidor de cinasa del receptor 1 del dominio de discoidina (ddr1) y medicamento
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240244A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
|
|
US20250345389A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|